Neuralstem, Inc. (CUR) Receives FDA Approval to Begin First ALS Stem Cell Trial

In the company’s news yesterday,

The company announced that the US Food & Drug Administration (FDA) has approved its investigational new drug application to commence a Phase 1 trial to treat ALS or Lou Gehrig’s disease with its spinal cord stem cells. Neuralstem is the first company to commence a stem cell trial to treat ALS. The disease affects roughly 30,000 people in the United States, with about 7,000 new diagnoses per year.

The trial will study the safety of Neuralstem’s cells and the surgical procedures and devices required for multiple injections of Neuralstem’s cells directly into the grey matter of the spinal cord. The FDA’s approval represents a significant step toward delivering regenerative medicine directly to damaged neural cells in humans.

Neuralstem’s CEO and president, Richard Garr, stated, “The beginning of our clinical trial program is a major step toward achieving Neuralstem’s goal of treating ALS, a fatal neurodegenerative disease for which currently there is no effective treatment or cure. While this trial aims to primarily establish safety and feasibility data in treating ALS patients, we also hope to be able to measure a slowing down of the ALS degenerative process.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.